Positive outcomes. Positive patient stories. These are our priorities at Paratek Pharmaceuticals. As a commercial-stage biopharmaceutical company, we develop transformative solutions for patients with infectious diseases and other difficult to treat conditions, and we believe that we have the right people, the right knowledge and the right drug to make a difference in patients’ lives.
Our Mission
To create positive stories for patients, physicians and caregivers based on trust and integrity. To accomplish this, our employees work hard to turn everyday decisions into everyday triumphs that advance our technology and strengthen Paratek.
Our Vision
To be a leading independent biopharmaceutical company providing novel life-saving products for life-threatening diseases or other public health threats.
Our Mission
To create positive stories for patients, physicians and caregivers based on trust and integrity. To accomplish this, our employees work hard to turn everyday decisions into everyday triumphs that advance our technology and strengthen Paratek.
Our Vision
To be a leading independent biopharmaceutical company providing novel life-saving products for life-threatening diseases or other public health threats.
Location: United States, Massachusetts, Boston
Employees: 51-200
Founded date: 1996
Investors 4
| Date | Name | Website |
| - | Aisling Ca... | aislingcap... |
| - | Omega Fund... | omegafunds... |
| 06.11.2022 | Hercules C... | htgc.com |
| - | Abingworth... | abingworth... |
Mentions in press and media 6
| Date | Title | Description |
| 05.03.2024 | Paratek Pharmaceuticals Announces Positive Efficacy Data for NUZYRA® as Post-Exposure Prophylaxis of Inhalational Anthrax, Triggering Additional Procurement under BARDA Project BioShield Contract | - |
| 25.09.2023 | Gurnet Point Capital and Novo Holdings Acquires Paratek Pharmaceuticals | Gurnet Point Capital and Novo Holdings A/S completed the acquisition of Paratek Pharmaceuticals (Nasdaq: PRTK), a Boston, MA-based commercial-stage biopharmaceutical company, in a transaction valued at $462m. Led by Evan Loh, M.D., Chief Ex... |
| 01.09.2022 | Paratek Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference | BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening disea... |
| 14.03.2022 | Paratek Pharmaceuticals Announces Full-Year 2021 Revenue of $130.2 Million | -- NUZYRA® (omadacycline) Generated Net U.S. Sales of $106.1 Million Comprised of $68.2 Million from the Core Commercial Business, a 76% increase over Prior Year, and $37.9 Million from the Initial Procurement of NUZYRA under the BARDA Bios... |
| 01.06.2021 | PARATEK PHARMACEUTICALS, INC. Paratek Pharmaceuticals Announces FDA Approval of NUZYRA® (omadacycline) Oral Only Dosing Regimen for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) | - Oral-only dosing for the Treatment of CABP Expands the Commercial Opportunity for Primary Care Promotion - Primary Care Market Opportunity for CABP Estimated at Approximately $1.5 Billion BOSTON, June 01, 2021 (GLOBE NEWSWIRE) -- Paratek ... |
| 17.05.2021 | PARATEK PHARMACEUTICALS, INC. Paratek Pharmaceuticals Announces First Quarter 2021 Total Revenue of $16.4 Million and Initiation of First BARDA Procurement | -- NUZYRA® (omadacycline) Generated Net U.S. Sales of $13.2 Million in the First Quarter 2021; 6% Increase Over the Fourth Quarter 2020 -- BARDA has Initiated the First Procurement of NUZYRA Valued at ~$38 Million in the Second Quarter of 2... |